Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Additionally, growing evidence suggests that neuroinflammation may modulate the effects of tau spread on cognitive impairment in AD [Peretti, Débora E., et al., Brain 147.12 (2024): 4094‐4104.]. Result 58(16,4%) participants were classified as p ‐tau217+, 176 (49,7%) as GFAP+, and 173(48,9%) showed GFAP fast.rate . Participants with p ‐tau217+ and higher annual GFAPfast.rate showed a significantly faster cognitive decline (βTime*pTau217*GFAP fast.rate = ‐0.158; p <0.001) than those with non‐GFAP fast.rate (Figure 1). However, baseline levels of GFAP and p ‐tau217 did not show a significant interaction (βTime*pTau217*GFAP baseline = ‐0.076; p = 0.094) (Figure 2). Conclusion Our results indicate that GFAP fast.rate modulates the relationship between p ‐tau217 and cognitive decline independently of age, sex and ApoE4, with a stronger decline observed in individuals with p ‐tau217+ who likely present a reactive astrogliosis.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 354 participants. In older adults, those with positive p-tau217 and a faster annual rise in GFAP showed significantly faster cognitive decline than those without a fast GFAP rise. Reported effect size: 61.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Valeriano-Lorenzo, E., Ricciardi, M. E., Wagner, S., Martinez, M., Frades, B., Zea‐Sevilla, M. A., et al. (2025). Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_106267

Vancouver

Valeriano-Lorenzo E, Ricciardi ME, Wagner S, Martinez M, Frades B, Zea‐Sevilla MA, et al. Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_106267.

BibTeX

@article{valerianolorenzo2025-ec93d4d3,
  author  = {Valeriano-Lorenzo, Elizabeth and Ricciardi, Mario Emiliano and Wagner, Sonia and Martinez, Minerva and Frades, Belén and Zea‐Sevilla, María Ascensión and Valenti, Meritxell and del Ser, Teodoro and others},
  title   = {{Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_106267},
  url     = {https://doi.org/10.1002/alz70856_106267}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In older adults, those with positive p-tau217 and a faster annual rise in GFAP showed significantly faster cognitive decline than those without a fast GFAP rise. Baseline GFAP and p-tau217 did not show a significant interaction, and the authors conclude that the rate of GFAP change modifies the link between p-tau217 and cognitive decline.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 44 of the 96 points it could be judged on, which is 46 of 100. Total 46 of 100.44 of the 96 points we could judge = 46 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 44 of the 96 points we could judge it on, which is 46 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 354 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Pascual Sanchez‐Juan holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Instituto de Salud Carlos III: institution h-index 649 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 44 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 96 points we could judge it on is 46 out of 100.
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →